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HNSCC is feasible while respecting strict dose constraints to 
OARs. By correcting for morphological and biological tumor 
changes during RT, higher conformity is ensured between the 
FDG uptake and the dose distributions. Clinical studies must 
be conducted to evaluate the acute and chronic toxicities 
and the tumor response of such a strategy.  
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Purpose/Objective: Current treatment of advanced cancer of 
the head and neck is unsatisfactory in terms of outcome and 
the toxicity of current treatments are severe. Phase III 
clinical trials have shown that hyperthermia (heating in the 
range of 40-44°C for one hour) is a potent sensitizing agent 
of radiotherapy, which is achieved without additional toxicity 
[1-3]. To enable heat-sensitization also in target regions at 
deep locations, we developed the HYPERcollar and showed in 
45 patients that inducing hyperthermia in tumors located 
deeply and laterally in the head and neck region is feasible 
and has potential. Over the years, we further introduced an 
adaptive hyperthermia strategy based on electromagnetic 
field simulations. In this study, we analyze the HYPERcollar3D 
that is a redesigned version of the HYPERcollar aimed at 
improving heating quality, heating reproducibility and patient 
comfort.  
Materials and Methods: In the HYPERcollar3D, patient 
comfort and treatment accuracy/stability are improved by 
splitting the waterbolus functions into a stable outer part and 
a patient conformal inner part. Patient positioning according 
to the CT resembles that of radiotherapy and is obtained by 
immobilization and a laser alignment procedure. Based on a 
mechanical redesign, we performed parameter studies using 
electromagnetic simulator SEMCAD-X (v. 14.8.6) to 
investigate further improvement by increasing the number of 
antennas and their locations.  
Results: The simulation studies showed that higher number of 
antennas, and their repositioning, allows for a substantially 
improved treatment quality. All improvements combined 
enable a predicted reduction of hotspot importance 
prominence (hot-spot target quotient (HTQ)) by 32%. 
Combining all systems improvements, simulations predict 
that a doubling of the clinically applied power to the target 
can be achieved. After clinical introduction, two patients 
(nasopharynx ca. and a neck node metastasis) have been 
treated with the HYPERcollar3D. Validation of heating 
performance by invasive thermometry in the tumor proved 
not possible but, in both patients, the scheduled treatments 
of 75 minutes could be completed using a mean applied 
power of 350-400W. In addition, the estimated SAR based on 
the realtime measured powers/phases of the signals was 
90W-200W/kg, which is beyond the long term average 
applied SAR using the conventional HYPERcollar, i.e. 75W/kg.  
Conclusions: Although the improvement still has to be 
validated by invasive temperature measurements in the 
tumor, these results are very reassuring that the 
HYPERcollar3D will provide a significant improvement in 
treatment quality. Hyperthermia is currently used as a 
standard addition to radiotherapy for patients that are re-
irradiated. A protocol for a clinical study in primary tumors is 
being finalized.  
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Purpose/Objective: To identify patterns of long-term, 
radiation-induced swallowing dysfunction after completion of 
definitive radiotherapy with or without chemotherapy (RT or 
CRT) and to determine which factors could explain these 
patterns over time. 
Materials and Methods: The study population consisted of 
238 consecutive head and neck cancer patients treated with 
RT or CRT. The primary endpoint was ≥ grade 2 swallowing 
dysfunction at 6, 12, 18 and 24 months after treatment. 
Cluster analysis was used to identify different patterns over 
time. The degree of swallowing dysfunction at baseline and 
at all subsequent time points (at 6, 12, 18 and 24 months) 
were considered for cluster modeling on the basis of their 
contribution to characterizing the patterns of late radiation-
induced swallowing dysfunction. The differences between the 
dose-volume histograms (DHVs) of the swallowing organs at 
risk for each pattern were determined by using dose maps. 
Results: The cluster analysis revealed five patterns of long-
term, radiation-induced swallowing dysfunction: low 
persistent, moderate persistent, severe persistent, transient 
and progressive (Figure 1). Patients with high dose to the 
upper pharyngeal, laryngeal and lower pharyngeal region had 
the highest risk of severe persistent swallowing dysfunction. 
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Transient problems mainly occurred after high dose to the 
laryngeal and lower pharyngeal regions, combined with 
moderate dose to the upper pharyngeal region. The 
progressive pattern was mainly seen after moderate dose to 
the upper pharyngeal region. 
 
 
Conclusions: After definitive RT or CRT, five different 
patterns of swallowing dysfunction can be identified over 
time. This could reflect different underlying radiobiological 
mechanisms of radiation-induced damage and recovery. 
These results may improve identifying patients who are at 
the highest risk for developing severe persistent swallowing 
problems and who may benefit most from different 
preventive measures, such as swallowing sparing IMRT.  
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Purpose/Objective: Head and neck carcinoma of unknown 
primary (HNCUP) metastatic to cervical lymph nodes (LNs) 
constitutes about 2% of all head and neck carcinomas. There 
is no consensus on a standard radiotherapy clinical target 
volume (CTV) (ipsilateral neck only vs bilateral neck and 
mucosal tube) or dose to the CTV (50-70Gy). The aim of this 
combined analysis was to assess the safety and feasibility of 
total mucosal and bilateral neck intensity modulated 
radiotherapy (TM-IMRT). 
Materials and Methods: We performed a combined analysis 
of 2 single arm, phase 2 prospective trials (CCR2823 and 
CCR3301). All patients (pts) had PET-CT or CT staging, pan-
endoscopy and tonsillectomy or biopsy to exclude an occult 
primary. Patients with stage T0, N1-3, M0 (AJCC TNM 2002) 
disease were treated using a 5- to 7-field IMRT technique. 
CTV1 was the ipsilateral level 1b-5 and retropharyngeal (RP) 
LNs. CTV2 was the mucosa of nasopharynx, oropharynx, 
larynx, hypopharynx and contralateral cervical level 2 to 5 
and RP LNs. Prescribed doses to PTV1 and PTV2 in 30 
fractions were 60-65 Gy (depending on resection status R0 – 
60Gy, R1/R2 – 65 Gy) and 54 Gy, respectively. No 
prophylactic enteric feeding tubes were inserted. 
Results: Thirty-six pts (53% male) with HNCUP, median age of 
54.2 years (range 43-86.9 years), were treated between July 
2007 and December 2012. Histology was squamous cell 
carcinoma (SCC) in 35 pts or undifferentiated carcinoma 
nasopharyngeal type in 1 pt. Twenty-five (69%) pts were p16-
positive (surrogate for HPV) and 18 (50%) pts had a ≥10 pack 
year smoking history. Eighteen (50%) pts received 
chemoradiotherapy with concomitant platinum and 18 
(50%)pts radiotherapy (RT) alone. The median treatment time 
was 41 days (range 39-46 days). All pts received the 
prescribed dose with no clinically significant delays. The 2 
year locoregional control rate was 89.8% (95% CI, 78.4-100). 
The 2 year primary mucosal and local nodal control rates 
were 97.1% (95% CI, 91.4-100) and 89.8% (95% CI, 78.4-100) 
respectively. One mucosal primary (oropharynx) was 
detected 7.3 months (m) after RT and 2 patients died from 
recurrent metastatic SCC at 5.7m and 16.4m after RT. 
Twelve pts (33%) had acute (<3m after RT) grade 3 (LENT-
SOMA) dysphagia. The 1 year enteric tube feeding rate was 1 
of 36 (2.7%) pts. Rates of high grade, subjective xerostomia 
(LENT-SOMA, ≥grade 2) at 12m and 24m after RT were 17% 
and 15% respectively. 
Conclusions:At a median follow up of 33.5 months the use of 
TM-IMRT treating the total mucosal tube to an elective 
radiation dose of 54 Gy was associated with good local 
control rates. Toxicity is improved compared to previously 
reported TM-IMRT regimens encompassing similar mucosal 
volumes.  
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Purpose/Objective: Tumor hypoxia is a common feature of 
locally advanced head and neck cancer (HNSCC) that is 
associated with higher malignancy and increased 
radioresistance. The resolution of tumor hypoxia during 
fractionated radiation treatment is assumed to be pivotal for 
treatment success. 18F-fluoromisonidazole PET (F-MISO PET) 
allows noninvasive assessment of hypoxia during treatment. 
The purpose of the present study was to noninvasively assess 
the time course of tumor hypoxia and its correlation with 
additional imaging modalities and outcome. 
Materials and Methods: A prospective serial imaging study 
was conducted in patients undergoing definitive 
radiochemotherapy (RCTx, total dose 70Gy) for locally 
advanced HNSCC, accompanied by Cisplatin in weeks 1, 4 and 
7. Tumor hypoxia was assessed by F-MISO-PET by static scans 
acquired 2.5 h p.i. Tumor volumes were determined for FDG 
PET scans and the coregistered F-MISO scans. At baseline MRI, 
FDG-PET and 1st F-MISO were acquired. Additional F-MISO 
scans were acquired in treatment weeks 2 and 5 (F-MISO2, 3). 
Endpoints were standardized uptake values (SUV) for PET 
scans, response on MRI scans (complete reponse (CR), partial 
